Associated Papers
The Contribution of Genetic Modifiers to Ovarian Cancer Risk in BRCA1 and BRCA2 Pathogenic Variant Carriers.
Cylwik D et al.
Cancers, 2026
Genetic susceptibility of bladder cancer in the Lebanese population.
Kourie HR et al.
Bmc Medical Genomics, 2022
Genetic variations in tumor ecrosis factor related apoptosis-inducing ligand receptor-1 (TRAIL-R1) gene and the susceptibility to b-cell non-hodgkin lymphoma (B-NHL) in Egypt.
Khorshied M et al.
Cancer Biomarkers : Section a of Disease Markers, 2021
Variants of genes encoding TNF receptors and ligands and proteins regulating TNF activation in familial multiple sclerosis.
Torre-Fuentes L et al.
Cns Neuroscience & Therapeutics, 2020
The Impact of TRAIL (C1595T and G1525A) and DR4 (rs20576) Gene Polymorphisms on Systemic Lupus Erythematosus.
Sandoughi M et al.
Biochemical Genetics, 2020
Genetic variations in death receptor domain 4 gene and the susceptibility to hepatitis C related hepatocellular carcinoma.
Zayed SA et al.
Journal of Medical Virology, 2019
Evaluation of trail receptor 1 (DR4) polymorphisms C626G and A683C as risk factors of hepatocellular carcinoma.
Alsalawy NF et al.
Journal of Medical Virology, 2018
Characterization of Disease-Associated Mutations in Human Transmembrane Proteins.
Molnár J et al.
Plos One, 2016
Death receptor 4 variants enhanced prostate cancer risk in North Indian population.
Mittal RD et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine, 2015
Identification of cancer predisposition variants in apparently healthy individuals using a next-generation sequencing-based family genomics approach.
Karageorgos I et al.
Human Genomics, 2015
Genetic polymorphisms and haplotypes of TRAIL gene correlate with NSCLC susceptibility in a group of Chinese patients.
Luo J et al.
International Journal of Clinical and Experimental Medicine, 2015
The eSNV-detect: a computational system to identify expressed single nucleotide variants from transcriptome sequencing data.
Tang X et al.
Nucleic Acids Research, 2014
Association of four polymorphisms in the death receptor 4 gene with cancer risk: an updated meta-analysis.
Lu J et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine, 2014
Association of polymorphisms in TRAIL1 and TRAILR1 genes with susceptibility to lymphomas.
Heredia-Galvez B et al.
Annals of Hematology, 2014
Death receptor (DR4) haplotypes are associated with increased susceptibility of gallbladder carcinoma in north Indian population.
Rai R et al.
Plos One, 2014
TRAIL-R1 is a negative regulator of pro-inflammatory responses and modulates long-term sequelae resulting from Chlamydia trachomatis infections in humans.
Al-Kuhlani M et al.
Plos One, 2014
Association of DR4 (TRAIL-R1) polymorphisms with cancer risk in Caucasians: an updated meta-analysis.
Chen W et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2014
Association between laryngeal squamous cell carcinoma and polymorphisms in tumor necrosis factor related apoptosis induce ligand (TRAIL), TRAIL receptor and sTRAIL levels.
Verim A et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2014
There is no significant association between death receptor 4 (DR4) gene polymorphisms and lung cancer in Turkish population.
Taştemir-Korkmaz D et al.
Pathology Oncology Research : Por, 2013
A Study of the Impact of Death Receptor 4 (DR4) Gene Polymorphisms in Alzheimer's Disease.
Edgünlü TG et al.
Balkan Medical Journal, 2013
Candidate gene study of TRAIL and TRAIL receptors: association with response to interferon beta therapy in multiple sclerosis patients.
López-Gómez C et al.
Plos One, 2013
Association of death receptor 4 variant (683A > C) with ovarian cancer risk in BRCA1 mutation carriers.
Dick MG et al.
International Journal of Cancer, 2012
TRAIL receptor I (DR4) polymorphisms C626G and A683C are associated with an increased risk for hepatocellular carcinoma (HCC) in HCV-infected patients.
Körner C et al.
Bmc Cancer, 2012
TRAIL-R1 polymorphisms and cancer susceptibility: an evidence-based meta-analysis.
Chen B et al.
European Journal of Cancer (oxford, England : 1990), 2009
Genetic variants in the death receptor 4 gene contribute to susceptibility to bladder cancer.
Wang M et al.
Mutation Research, 2009
TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5.
Zhang Y et al.
Molecular Cancer Research : Mcr, 2008
Metastatic susceptibility locus, an 8p hot-spot for tumour progression disrupted in colorectal liver metastases: 13 candidate genes examined at the DNA, mRNA and protein level.
Macartney-Coxson DP et al.
Bmc Cancer, 2008
The Glu228Ala polymorphism in the ligand-binding domain of death receptor 4 is not associated with rheumatoid arthritis.
Yazdani-Biuki B et al.
Annals of the Rheumatic Diseases, 2008
The Glu228Ala polymorphism in the ligand binding domain of death receptor 4 is associated with increased risk for prostate cancer metastases.
Langsenlehner T et al.
The Prostate, 2008
Death receptor 4 variants and colorectal cancer risk.
Frank B et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 2006
Ala228 variant of trail receptor 1 affecting the ligand binding site is associated with chronic lymphocytic leukemia, mantle cell lymphoma, prostate cancer, head and neck squamous cell carcinoma and bladder cancer.
Wolf S et al.
International Journal of Cancer, 2006
Association of death receptor 4 haplotype 626C-683C with an increased breast cancer risk.
Frank B et al.
Carcinogenesis, 2005
Mutation analysis of the apoptotic "death-receptors" and the adaptors TRADD and FADD/MORT-1 in osteosarcoma tumor samples and osteosarcoma cell lines.
Dechant MJ et al.
International Journal of Cancer, 2004